Skip to main content

Table 2 Changes in LDLC and CVD risk from study entry to last follow up in 72 patients taking Alirocumab or Evolocumab

From: Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

  Alirocumab 75 mg (n = 25) Follow up length median 24 weeks Alirocumab 150 mg (n = 15) Follow up length median 26 weeks Evolocumab 140 mg (n = 32) Follow up length median 24 weeks
Variable measured percentile percentile percentile
25th 50th 75th 25th 50th 75th 25th 50th 75th
LDLC Entry (mg/dl) 100 117 143 133 175 214 143 165 211
Follow up (mg/dl) 47 62 84 49 57 86 46 69 109
Absolute change (mg/dl) −35 −67 −85 −89 −104 −141 −65 −89 −131
 P (paired Wilcoxon) p <.0001 p <.0001 p <.0001
Percent change (%) −27 −54 −63 −56 −63 −72 −40 −63 −71
  P (Wilcoxon) p <.0001 p <.0001 p <.0001
CVD risk for next 10 years With AHA calculator Entry (%) 3.9 6.2 18.0 5.4 9.3 20.4 4.3 11.5 18.6
Follow up (%) 3.3 6.2 10.1 2.3 7.0 15.1 2.9 6.7 20.2
Absolute change −0.2 −1.6 −5.4 −0.7 −3.3 −6.0 −0.6 −2.4 −5.7
 P (paired Wilcoxon) p = .0001 p = .0043 p = <.0001
Percent change −1.9 −22.2 −40.7 −22.2 −31.3 −39.0 −9.1 −28.7 −52.3
  P (Wilcoxon) p = .0002 p = .0015 p <.0001
CVD risk for next 10 years With NIH calculator Entry (%) 6.8 11.2 19.8 10.6 17.2 25.7 9.6 17.4 26.4
Follow up (%) 4.3 7.4 11.7 5.1 6.5 12.3 5.3 8.0 12.0
Absolute change −1.4 −4.2 −10.5 −4.4 −9.1 −16.2 −3.0 −7.1 −14.7
 P (paired Wilcoxon) p <.0001 p = .0001 P <.0001
Percent change −21.4 −43.7 −53.5 −41.6 −49.8 −61.4 −27.9 −55.5 −66.2
  P (Wilcoxon) p <.0001 p = .0001 p <.0001